Hypertrophic Cardiomyopathy in the Older Age Group: The Effect of Cardiometabolic Risk Factors and Rs2290149 and Rs10838692 of the Madd Gene

Полякова, А. А.; Гудкова, А. Я.; Krutikov, A. N.; Semernin, E. N.; Козленок, А. В.; Pyko, Svetlana A.; Kostareva, Anna; Шляхто, Е. В.

doi:10.18705/1607-419x-2018-24-1-29-40

Cited by 7 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Вместе с тем распространенность этих заболеваний существенно выше. Так, для ГКМП это 1:200-500, а при использовании таких современных методов диагностики, как МРТ, КТ и генетическое тестирование -1:167 [22][23][24]. Частота встречаемости АДПЖ составляет от 1:5000 до 6:10000 [25,26].…”

Section: Discussionunclassified

Clinical and anamnestic characteristics of patients with an implanted cardioverter-defibrillator in real clinical practice (data from the Kuzbass register)

et al. 2021

View full text Add to dashboard Cite

Aim To study the consistency of the practice of management, selection and routing of patients at high risk of sudden cardiac death (SCD) selected for cardioverter-defibrillator implantation (CDI) with current clinical guidelines and to evaluate the quality of subsequent outpatient follow-up and treatment based on a retrospective analysis of clinical amnestic data from the Kuzbass Registry of Patients with CDI.Material and methods The study was based on the Registry of Patients with Implanted Cardioverter Defibrillator and included successive data of 28 patients hospitalized to the Kizbass Cardiological Center from 2015 through 2019. Social and clinical amnestic characteristics, indications for CVI, and concomitant drug therapy were analyzed retrospectively. Statistical analyses were performed with the Statistica 10.0 software (Statsoft, USA).Results Median age of patients was 59 (53; 66) years; 239 (83.6 %) men were included; 29 (10.1%) people were employed, CHI was performed in 182 (63.6 %) patients for prevention of SCC, and for secondary prevention in 104 (36.4 %) patients. 208 (72.7 %) patients were diagnosed with ischemic heart disease (IHD), and 145 (67.9 %) of them underwent myocardial revascularization. Noncoronarogenic diseases were found in 78 (27.3 %) patients, and most of them were diagnosed with dilated cardiomyopathy. All patients had chronic heart failure (CHF); half of them had stage IIA CHF. Median left ventricular ejection fraction was 30 (25; 36,5) % according to echocardiography using the Simpson method. Comorbidity was found in 151 (52.8 %) patients. 128 (44.8%) patients received a triple neurohormonal blockade for CHF treatment; titration to target doses was not performed in any of them. Antiarrhythmics were administered to 150 (52.4 %) patients.Conclusion According to the data from the Kuzbass Registry of CVI, the main patient cohort consisted of men of pension age with IHD and CHF. Before CVI, more than a half of them had not received an optimum drug therapy and not all of them had received target lesion revascularization. Creating and analysis of Registries of CHI patients is an effective method for identifying existing problems in patient management before CVI and for optimizing their subsequent follow-up and treatment.

show abstract

Section: Discussionunclassified

Clinical and anamnestic characteristics of patients with an implanted cardioverter-defibrillator in real clinical practice (data from the Kuzbass register)

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Генетическое тестирование на ГКМП или на другие причины необъяснимой ГЛЖ рекомендовано пациентам с атипичной клинической картиной ГКМП и в случаях, когда другое генетическое заболевание может быть причиной (класс I, уровень доказательности В). Фенотипические проявления КМП часто зависят от влияния генов-модификаторов, возраста, пола, коморбидности, факторов среды [12][13][14][15][16][17][18][19].…”

unclassified

Hypertrophic cardiomyopathy: modern aspects of pharmacologic treatment

Гудкова

Яковлевна²,

Streltsova

et al. 2019

Terapevticheskii arkhiv

View full text Add to dashboard Cite

show abstract

2020 Clinical practice guidelines for Hypertrophic cardiomyopathy

Габрусенко¹,

Гудкова²,

Козиолова³

et al. 2021

Russ J Cardiol

Self Cite

View full text Add to dashboard Cite

Russian Society of Cardiology (RSC)With the participation: Russian Association of Cardiovascular SurgeonsEndorsed by: Research and Practical Council of the Ministry of Health of the Russian Federation Task Force: Gabrusenko S.A. (Chairman), Gudkova A.Ya.* (Chairman), Koziolova N.A. (Chairman), Alexandrova S.A., Berseneva M.I., Gordeev M.L., Dzemeshkevich S.L., Zaklyazminskaya E.V., Irtyuga O.B., Kaplunova V.Yu., Kostareva A.A., Krutikov A.N., Malenkov D.A., Novikova T.N., Saidova M.A., Sanakoev M.K., Stukalova O.V.

show abstract

Hypertrophic Cardiomyopathy in the Older Age Group: The Effect of Cardiometabolic Risk Factors and Rs2290149 and Rs10838692 of the Madd Gene

Cited by 7 publications

References 0 publications

Clinical and anamnestic characteristics of patients with an implanted cardioverter-defibrillator in real clinical practice (data from the Kuzbass register)

Clinical and anamnestic characteristics of patients with an implanted cardioverter-defibrillator in real clinical practice (data from the Kuzbass register)

Hypertrophic cardiomyopathy: modern aspects of pharmacologic treatment

2020 Clinical practice guidelines for Hypertrophic cardiomyopathy

Contact Info

Product

Resources

About